Judge weighs whether prisons can phase out hormone drugs for transgender inmates
A federal judge is reviewing a policy from the Trump administration that aims to phase out taxpayer-funded hormone treatments for transgender inmates. The judge questioned whether the Bureau of Prisons intends to completely discontinue hormone therapy for inmates, while the Justice Department argued that the policy allows for individualized treatment plans. This case is part of a broader legal challenge against the administration's executive order restricting transgender medical treatments in federal prisons.
- ▪The judge is considering the legality of a new Bureau of Prisons policy on transgender hormone treatments.
- ▪The Justice Department claims the policy allows for individualized tapering plans for inmates.
- ▪The lawsuit includes violent offenders seeking continued access to hormone therapy.
Opening excerpt (first ~120 words) tap to expand
A federal judge on Wednesday considered whether the Trump administration can move forward with a new Bureau of Prisons policy designed to phase out taxpayer-funded transgender drugs for federal inmates. During a hearing in Washington, U.S. District Judge Royce Lamberth, an appointee of former President Ronald Reagan, repeatedly pressed the Justice Department over whether BOP’s ultimate goal is to remove inmates from cross-sex hormones entirely. Recommended Stories Homan proposes force-feeding ICE detainees on hunger strike: ‘We’ll get a court order’ Tom Cotton warns FDA about cybersecurity threat from Chinese-made medical devices Wes Moore inks bill guaranteeing emergency abortion access in hospitals “So the goal is to eventually taper even post-surgery patients totally off?” Lamberth…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Examiner.
Discussion
0 commentsMore from Washington Examiner
